- Born:
- August 7, 1948, Alice, Texas, U.S. (age 78)
- Awards And Honors:
- Nobel Prize (2018)
- Subjects Of Study:
- CTLA-4
- T cell
- amino acid
- antibody
- cancer
- immune system
- melanoma
James P. Allison
-
Who is James P. Allison?
James P. Allison, born on August 7, 1948, is an American immunologist known for his contributions to understanding T-cell activation mechanisms and his pioneering work in immune checkpoint therapy for cancer.
Allison's research focused on how T cells recognize foreign particles or antigens. He identified CD28 as a necessary costimulatory signaling molecule for T-cell activation and discovered that CTLA-4 opposed CD28, playing a crucial role in downregulating immune responses. Blocking CTLA-4 activity with antibodies enhanced T-cell responses and led to tumor shrinkage in mice, an approach known as immune checkpoint blockade.
His work led to the development of ipilimumab, a human monoclonal antibody against CTLA-4, which became the first immune checkpoint therapy approved by the U.S. Food and Drug Administration in 2011 for treating late-stage melanoma. Allison shared the 2018 Nobel Prize for Physiology or Medicine with Tasuku Honjo for his discoveries.
4 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What field of science does James P. Allison work in?
James P. Allison is an American immunologist known for his contributions to understanding T-cell activation mechanisms and his pioneering work in immune checkpoint therapy for cancer. His research focuses on harnessing the body's immune system to combat diseases. Specifically, Allison's work involves understanding how T cells recognize foreign particles or antigens. He shared the 2018 Nobel Prize for Physiology or Medicine with Tasuku Honjo for his discoveries. Immunology is the study of the body's defense against disease-causing microorganisms and disorders in the immune system's functioning. T-cells are essential to the immune system.
5 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What are immune cells and why are they important?
Immune cells, such as T cells and granulocytes, are essential to the immune system. They protect the body by identifying and eliminating foreign substances, including viruses, bacteria, and cancerous cells.
James P. Allison, an American immunologist, significantly contributed to understanding T-cell activation and developing immune checkpoint therapy for cancer. His work revealed how to unleash the immune system to target and destroy tumors, marking a significant advancement in immunotherapy.
5 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What major discovery did James P. Allison make about the immune system?
James P. Allison discovered that blocking the activity of the molecule cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) enhanced T-cell responses and led to tumor shrinkage in mice. This strategy, known as immune checkpoint blockade, became a focal point of Allison's research. His work led to the development of ipilimumab, a human monoclonal antibody against CTLA-4. In 2011, it became the first immune checkpoint therapy approved by the U.S. Food and Drug Administration for treating late-stage melanoma. For this discovery, Allison shared the 2018 Nobel Prize in Physiology or Medicine with Tasuku Honjo.
6 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
How did James P. Allison’s research lead to new treatments for cancer?
James P. Allison's research led to new cancer treatments through his discovery of immune checkpoint therapy. His work centered on understanding how T cells recognize foreign particles or antigens. Allison identified CD28 as a necessary costimulatory signaling molecule for T-cell activation and found that CTLA-4 opposed CD28, downregulating immune responses.
Allison's experiments injecting CTLA-4 antibody into mice tumors enhanced T-cell responses, shrinking the tumors, an approach known as immune checkpoint blockade. He developed a human monoclonal antibody against CTLA-4 (ipilimumab), which became the first immune checkpoint therapy approved by the FDA in 2011 for late-stage melanoma. This therapy releases inhibitory signals, augmenting the immune response and enabling tumor destruction.
5 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What important awards or recognitions has James P. Allison received for his work?
James P. Allison is an American immunologist known for his contributions to understanding T-cell activation mechanisms and his pioneering work in developing immune checkpoint therapy for cancer.
Key awards and recognition:
* 2018 Nobel Prize for Physiology or Medicine (shared with Tasuku Honjo)
* Canada Gairdner International Award (2014)
* Louisa Gross Horwitz Prize (2014)
* Elected member of the National Academy of Sciences (1997)
* Elected member of the American Association for the Advancement of Science (2006)
* Elected member of the National Academy of Medicine (2007)3 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.
James P. Allison (born August 7, 1948, Alice, Texas, U.S.) is an American immunologist who contributed to the discovery of mechanisms underlying T-cell activation and who was a pioneer in the development of immune checkpoint therapy for cancer. For his discoveries, Allison shared the 2018 Nobel Prize for Physiology or Medicine with Japanese immunologist Tasuku Honjo.
At age 15, Allison participated in a science-training program at the University of Texas at Austin (UT Austin), which fueled his already developing interest in science. He later earned a B.S. degree (1969) in microbiology and a Ph.D. (1973) in biological sciences from UT Austin and completed a postdoctoral fellowship at Scripps Clinic and Research Foundation (later renamed Scripps Research Institute) in La Jolla, California. At Scripps, Allison worked primarily on amino acid sequencing but also found time to carry out experiments on immune cell function. These experiments led to his first major discovery concerning tumour recognition by the immune system.
In the mid-1970s, Allison moved to the University of Texas MD Anderson Cancer Center, joining the faculty there as an assistant biochemist. His research centred on elucidating the mechanism by which T cells recognize foreign particles, or antigens. During this time, he also successfully mapped the structure of the T-cell antigen receptor. In 1985, after transitioning between positions at UT Austin, Stanford University, and MD Anderson, Allison decided to accept a full professorship in immunology at the University of California, Berkeley. In his laboratory there, he identified CD28 as a necessary costimulatory signaling molecule required for T-cell activation. He and colleagues also found that a molecule known as CTLA-4 opposed CD28 and played a critical role in the downregulation of immune responses. When injected into tumours in mice, CTLA-4 antibody, designed to block CTLA-4 activity, enhanced T-cell responses and led to tumour shrinkage. This approach to boosting immune responses subsequently became known as immune checkpoint blockade. Allison increasingly focused his research on better understanding the effects of CTLA-4 blockade.
As Allison was carrying out his work on CTLA-4 inhibition, he moved from Berkeley to Weill Cornell Medical College in New York City, where, from 2006 to 2012, he also served as director of the Ludwig Center for Cancer Immunotherapy at the Memorial Sloan Kettering Cancer Center. While there, he worked with a pharmaceutical company to develop a human monoclonal antibody against CTLA-4 (ipilimumab) for use in cancer patients. In 2011, under the trade name Yervoy, the antibody became the first immune checkpoint therapy to be approved by the U.S. Food and Drug Administration; it was approved for the treatment of late-stage melanoma.
In 2012, Allison returned to MD Anderson Cancer Center, where he served as the Vivian L. Smith Distinguished Chair in Immunology and as Director of the Parker Institute for Cancer Immunotherapy. In addition to the Nobel Prize, Allison was the recipient of numerous other awards, including the Canada Gairdner International Award (2014) and the Louisa Gross Horwitz Prize (2014). He was an elected member of multiple organizations, including the National Academy of Sciences (1997), the American Association for the Advancement of Science (2006), and the National Academy of Medicine (2007).